---
title: "Cullinan Therapeutics: Zipalertinib + chemo cuts median PFS to 14.5 vs 8.5 months in REZILIENT3"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/298911659.md"
description: "Cullinan Therapeutics announced that zipalertinib combined with chemotherapy significantly improved median progression-free survival (PFS) to 14.5 months versus 8.5 months for chemotherapy alone in the Phase 3 REZILIENT3 trial for first-line EGFR ex20ins NSCLC patients. The combination also showed a higher objective response rate (65.0% vs. 40.3%). Safety data indicated no new signals, though Grade ≥3 adverse events were more frequent with the combination therapy."
datetime: "2026-09-14T11:33:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/298911659.md)
  - [en](https://longbridge.com/en/news/298911659.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/298911659.md)
generator: "portal-rs"
---

# Cullinan Therapeutics: Zipalertinib + chemo cuts median PFS to 14.5 vs 8.5 months in REZILIENT3

**Cullinan Therapeutics announced zipalertinib plus chemotherapy delivered a significant median PFS improvement of 14.5 vs. 8.5 months in the Phase 3 REZILIENT3 trial.**

**Key Highlights:**

-   REZILIENT3 randomized 279 first-line EGFR ex20ins NSCLC patients to zipalertinib 100mg BID + chemo (n=140) or chemo alone (n=139).
-   Interim analysis (122 PFS events): median PFS 14.5 vs. 8.5 months; HR 0.50; 95% CI 0.34–0.73; P=0.00015.
-   Objective response rate 65.0% with combination vs. 40.3% with chemo; longer median duration of response (14.2 vs. 9.9 months).
-   Interim overall survival HR 0.72 (30% maturity; 95% CI 0.42–1.23); follow-up ongoing to further characterize OS.
-   Safety: no new signals; Grade ≥3 AEs higher with combination (87.1% vs. 54.4%), largely hematologic (58.6% vs. 28.7%); EGFR-related Grade ≥3 rash 10.7%, diarrhea 1.4%.

Original SEC Filing: Cullinan Therapeutics, Inc. \[ CGEM \] - 8-K - Sep. 14, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [CGEM.US](https://longbridge.com/en/quote/CGEM.US.md)

## Related News & Research

- [Cullinan Highlights Positive Phase 3 Lung Cancer Results](https://longbridge.com/en/news/298914860.md)
- [CGEM: Zipalertinib plus chemotherapy doubled progression-free survival in EGFR exon 20 insertion NSCLC](https://longbridge.com/en/news/298907946.md)
- [Cullinan Therapeutics CSO Jennifer Michaelson disposes 8,000 common shares worth $172,560](https://longbridge.com/en/news/298603820.md)
- [Otsuka’s Zipalertinib Combo Delivers Strong Phase 3 Lung Cancer Results](https://longbridge.com/en/news/298842929.md)
- [Zipalertinib Plus Chemotherapy Significantly Extends Progression-Free Survival in First-Line EGFR Exon 20 Insertion-Positive NSCLC](https://longbridge.com/en/news/298939567.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**